A61K 31/4375
The heterocyclic ring system containing a six-membered ring having nitrogen as a
Official title: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K31/4375 (The heterocyclic ring system containing a six-membered ring having nitrogen as a) appears on 1,247 US grants and 2,409 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,247
- Published applications
- 2,409
- Assignees
- 1,052
- Inventors
- 5,641
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 8 | 0 |
| 1999 | 4 | 0 |
| 2000 | 4 | 0 |
| 2001 | 6 | 2 |
| 2002 | 8 | 12 |
| 2003 | 5 | 33 |
| 2004 | 7 | 24 |
| 2005 | 7 | 28 |
| 2006 | 11 | 36 |
| 2007 | 9 | 29 |
| 2008 | 8 | 32 |
| 2009 | 6 | 26 |
| 2010 | 13 | 56 |
| 2011 | 23 | 57 |
| 2012 | 29 | 56 |
| 2013 | 36 | 93 |
| 2014 | 50 | 110 |
| 2015 | 71 | 135 |
| 2016 | 94 | 153 |
| 2017 | 95 | 135 |
| 2018 | 97 | 143 |
| 2019 | 99 | 158 |
| 2020 | 104 | 137 |
| 2021 | 86 | 125 |
| 2022 | 69 | 137 |
| 2023 | 78 | 164 |
| 2024 | 92 | 208 |
| 2025 | 77 | 179 |
| 2026 | 43 | 141 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto15 Sep 2026US 12,734,145 B2Children's Healthcare of Atlanta, Inc.
- Use of nucleotide synthesis inhibitors for targeted therapy in MLL3/4 compass mutant cancer15 Sep 2026US 12,734,173 B2Northwestern University
- Therapeutic methods for preventing tumor metastasis and tumor recurrence8 Sep 2026US 12,728,104 B2Lunella Biotech, Inc.
- Compounds for the treatment of bacterial infections and potentiation of antibiotics8 Sep 2026US 12,728,105 B2Georgia State University Research Foundation, Inc.
- Methods and compositions for the treatment of corneal endothelium disorders8 Sep 2026US 12,728,118 B2The Schepens Eye Research Institute, Inc.
- Glp-1r agonist and dpp-4 inhibitor compositions and methods of using8 Oct 2026US 2026/0306423 A1JDS Therapeutics, LLC
- Substituted nucleoside analogs as prmt5 inhibitors8 Oct 2026US 2026/0306479 A1Lupin Limited
- Anti-cancer treatments and methods of use thereof8 Oct 2026US 2026/0308535 A1
- Composition for treating ototoxic hearing loss caused by aminoglycoside antibiotics1 Oct 2026US 2026/0294880 A1Industry-Academic Coorperation Foundation Daegu Haany University
- Methods of treating migraine1 Oct 2026US 2026/0294881 A1Allergan Pharmaceuticals International Limited
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase132US 5,656,643 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997
- Water soluble paclitaxel derivatives122US 6,730,699 B2PG-TXL Company, L. P. · 2004
- Modulators of cystic fibrosis transmembrane conductance regulator94US 8,188,283 B2Vertex Pharmaceuticals Incorporated · 2012
- Inhibitors of the fibroblast growth factor receptor89US 8,802,697 B2Blueprint Medicines Corporation · 2014